Voyager Therapeutics Inc (NASDAQ:VYGR) – Research analysts at Wedbush issued their Q2 2020 EPS estimates for shares of Voyager Therapeutics in a research note issued to investors on Monday, August 12th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.80) per share for the quarter. Wedbush has a “Outperform” rating and a $36.00 price objective on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q3 2020 earnings at ($0.84) EPS and Q4 2020 earnings at ($0.87) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Friday, August 9th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $1.17. Voyager Therapeutics had a negative net margin of 106.23% and a negative return on equity of 82.98%. The firm had revenue of $46.09 million for the quarter, compared to analyst estimates of $5.25 million.

A number of other research analysts have also weighed in on VYGR. Morgan Stanley raised their price objective on shares of Voyager Therapeutics from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a research note on Monday. Nomura reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday. Finally, BidaskClub lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Voyager Therapeutics currently has an average rating of “Buy” and a consensus price target of $27.50.

Voyager Therapeutics stock opened at $20.62 on Wednesday. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $28.79. The firm has a market capitalization of $791.41 million, a price-to-earnings ratio of -7.50 and a beta of 2.55. The firm’s fifty day moving average price is $24.00 and its two-hundred day moving average price is $20.68.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC increased its holdings in Voyager Therapeutics by 1.0% during the first quarter. Acadian Asset Management LLC now owns 46,500 shares of the company’s stock worth $890,000 after buying an additional 469 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Voyager Therapeutics during the second quarter worth about $27,000. NumerixS Investment Technologies Inc purchased a new stake in Voyager Therapeutics during the second quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Voyager Therapeutics by 371.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,126 shares of the company’s stock worth $58,000 after buying an additional 1,675 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Voyager Therapeutics by 15.8% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,174 shares of the company’s stock worth $252,000 after buying an additional 1,794 shares during the last quarter. 73.92% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Read More: Asset Allocation

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.